A Phase II Evaluation Of Pemetrexed (ALIMTA, LY231517, IND #40061) In the Treatment Of Recurrent Carcinoma Of The Cervix

Trial Profile

A Phase II Evaluation Of Pemetrexed (ALIMTA, LY231517, IND #40061) In the Treatment Of Recurrent Carcinoma Of The Cervix

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Apr 2014

At a glance

  • Drugs Pemetrexed (Primary)
  • Indications Cervical cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Aug 2008 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
    • 08 Feb 2008 Status changed from in progress to discontinued; according to clinicaltrials.gov.
    • 06 Aug 2007 Status change from suspended to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top